HC Wainwright Weighs in on Axsome Therapeutics, Inc.’s Q3 2025 Earnings (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for Axsome Therapeutics in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.47 per share for the quarter, down from their prior estimate of $0.51. HC Wainwright has a “Buy” rating and a $190.00 price objective on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at $1.33 EPS.

A number of other equities research analysts have also recently commented on AXSM. Guggenheim increased their price target on Axsome Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Robert W. Baird lifted their target price on shares of Axsome Therapeutics from $108.00 to $112.00 and gave the stock an “outperform” rating in a research note on Tuesday. Morgan Stanley upgraded shares of Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $90.00 to $115.00 in a research note on Monday, April 29th. Piper Sandler lifted their price objective on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 16th. Finally, UBS Group initiated coverage on Axsome Therapeutics in a research report on Tuesday, February 6th. They issued a “buy” rating and a $111.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $121.92.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $73.68 on Thursday. Axsome Therapeutics has a 12 month low of $55.02 and a 12 month high of $98.40. The stock has a fifty day moving average price of $73.84 and a 200-day moving average price of $75.72. The company has a current ratio of 3.63, a quick ratio of 3.52 and a debt-to-equity ratio of 0.93. The firm has a market cap of $3.50 billion, a PE ratio of -11.55 and a beta of 1.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.48. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. The company had revenue of $71.53 million during the quarter, compared to analysts’ expectations of $70.38 million.

Insiders Place Their Bets

In other news, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Axsome Therapeutics news, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roger Jeffs sold 29,976 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the transaction, the director now owns 120,756 shares in the company, valued at approximately $8,416,693.20. The disclosure for this sale can be found here. Insiders own 24.50% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds have recently modified their holdings of the business. Washington Trust Advisors Inc. acquired a new position in Axsome Therapeutics during the fourth quarter worth about $26,000. Fifth Third Bancorp boosted its holdings in shares of Axsome Therapeutics by 100.0% during the 3rd quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Axsome Therapeutics by 5,550.0% in the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after purchasing an additional 777 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Axsome Therapeutics by 110.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,204 shares of the company’s stock valued at $84,000 after purchasing an additional 633 shares during the last quarter. Finally, Janiczek Wealth Management LLC purchased a new position in Axsome Therapeutics during the first quarter worth approximately $97,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.